No Data
No Data
Ch Biotech Ser (08037.HK) announced significant capital injection and stock-based incentive plan.
Ch Biotech Ser (08037.HK) released an announcement that on August 5, 2024, Pengbo (Hainan) (Pengbo (Hainan) Boron Neutron Medical Technology Co., Ltd., is an indirectly wholly-owned subsidiary of the company), Dynamic Healthcare, Pengbo (Pengbo (Hong Kong) Neutron Cancer Treatment Center Limited
Express News | China Biotech Services - Hubei Weiyou to Contribute up to RMB242.3 Mln in Pengbo (Hainan) to Subscribe for 35% Stake in Pengbo
Express News | China Biotech Services - Registered Capital of Pengbo (Hainan) Would Be Increased to RMB231 Mln
Express News | China Biotech Services - Capital Injection in and- Deemed Disposal of Equity Interest in- Pengbo (Hainan) Medical Technology
Ch biotech ser (08037.HK) issued a profit warning: expected to incur a mid-term loss of approximately HKD 81 million.
China Biotech Ser (08037.HK) announced that for the six months ended June 30, 2024 ("2024 Mid-Year Period"), the Group is expected to record a net loss attributable to owners of approximately HKD 81 million ("Loss"), compared to a net loss of approximately HKD 30.484 million for the six months ended June 30, 2023, representing a significant increase of approximately HKD 50.516 million in net loss attributable to owners. The board of directors believes that the increased net loss during the 2024 Mid-Year Period is mainly due to (i) post-pandemic situation.
Express News | China Biotech Services - Expected Result From Increase of HK$4.4 Mln in R&D Costs From Chimeric Antigen Receptor T-Cell Segment, Others
No Data